The 50% hemolysis rate test, most commonly reported as the CH50 assay (50% complement hemolytic activity), is a fundamental laboratory method for evaluating the functional integrity of the complete classical complement pathway in serum. This technical article provides a detailed analysis of 50% hemolysis rate test reports, covering sample requirements, testing items, analytical methodologies, result interpretation, and clinical applications. Understanding how these reports are generated and what their numerical results signify is essential for laboratory professionals, clinicians, and researchers working with complement-related diagnostics.
Technical Overview
The 50% hemolysis rate, referred to as CH50 (50% complement hemolytic activity), measures the total functional activity of the classical complement pathway in a serum sample. The assay is based on the ability of complement proteins, when activated by antigen-antibody complexes, to assemble the membrane attack complex (C5b-9) and lyse antibody-sensitized sheep erythrocytes. One CH50 unit is defined as the reciprocal of the serum dilution that produces 50% lysis of a standardized erythrocyte suspension under tightly controlled reaction conditions.
The selection of the 50% hemolysis endpoint, rather than complete (100%) lysis, is a deliberate scientific choice. The dose-response relationship between complement concentration and the percentage of cells lysed follows a sigmoidal curve, which is mathematically described by the Von Krogh equation. The steepest, most linear portion of this curve occurs at approximately 50% hemolysis, meaning that this endpoint provides maximum analytical sensitivity to small changes in complement concentration. At the extremes of the curve, large changes in complement activity produce only negligible changes in observable lysis, making 0% or 100% endpoints unsuitable for precise quantification.
A complete and well-structured CH50 test report should contain the following core elements:
- Patient or sample identification, collection date, and receipt date
- Specimen type and documented sample condition upon arrival
- Analytical method employed and measurement wavelength
- Quantitative result expressed in CH50 units per milliliter (U/mL) or equivalent units
- Laboratory-established reference interval for interpretation
- Quality control status, including validity of standards and controls
- Interpretive commentary, particularly for abnormally low or absent activity
Because the test is functional rather than purely immunological, it uniquely detects deficiencies in any classical pathway component from C1q through C9, since the entire cascade must be intact for hemolysis to occur.
Testing Samples
Serum Sample Requirements
Functional CH50 testing requires a serum specimen collected into a plain tube without anticoagulant. Venous blood is allowed to clot at room temperature for 30 to 60 minutes, followed by prompt centrifugation and serum separation, ideally within two hours of collection. Anticoagulants such as EDTA and citrate chelate calcium ions that are essential for classical pathway activation, making plasma unsuitable for functional hemolytic assays.
Sample Handling and Storage
Complement proteins are thermally labile and are readily degraded or spontaneously activated at room temperature. Accepted handling practice includes the following:
- Testing fresh serum on the day of collection whenever possible
- Short-term storage at 2-8 degrees Celsius for no more than 24 hours
- Long-term storage at -70 degrees Celsius or colder in aliquots
- Avoidance of repeated freeze-thaw cycles, which progressively reduce measured activity
- Transport under validated cold-chain conditions with temperature monitoring
Unsuitable Specimens
Grossly hemolyzed samples must be rejected because hemoglobin released from in vitro red cell rupture interferes directly with the absorbance measurement of the hemolysis supernatant. Severely lipemic or icteric samples may also cause optical interference. Reports should explicitly flag any specimen condition that could compromise result validity.
Testing Items
The primary testing item is total classical complement pathway activity expressed as CH50 in U/mL. A comprehensive complement evaluation performed by accredited third-party laboratories typically bundles related items to enable differential interpretation:
- CH50: total classical pathway functional activity
- AH50: alternative pathway functional activity, measured using unsensitized rabbit or guinea pig erythrocytes
- C3 and C4 concentrations: quantified individually by immunoturbidimetry or nephelometry
- Complement activation fragments such as C3a, C5a, and SC5b-9, where assessment of in vivo activation is required
- C1 inhibitor testing when hereditary angioedema is suspected
The combined CH50 and AH50 pattern is diagnostically powerful: a selective decrease in CH50 with preserved AH50 localizes the defect to early classical components (C1q, C1r, C1s, C2, or C4), whereas a decrease in both pathways indicates terminal pathway (C3 through C9) deficiency or global complement consumption.
Testing Methods
Classical Tube Dilution Hemolytic Assay (Mayer Method)
The reference functional method proceeds through the following steps:
- Sheep erythrocytes are washed and standardized to a defined cell concentration, then sensitized with an optimally diluted rabbit anti-sheep erythrocyte antiserum (hemolysin) to produce EA cells
- Serial dilutions of patient serum are prepared in isotonic veronal-buffered saline containing calcium and magnesium
- Diluted serum is mixed with a fixed volume of standardized EA cells and incubated at 37 degrees Celsius for 30 to 60 minutes
- Following centrifugation, the absorbance of the supernatant is measured spectrophotometrically at approximately 541 nm, the hemoglobin absorption maximum
- Blank (0% lysis, buffer only) and total lysis (100%, water or detergent) controls are run in parallel
- Fractional hemolysis values are transformed and plotted according to the Von Krogh relationship, and the dilution producing 50% lysis is interpolated
- CH50 activity is calculated as the reciprocal of that dilution and reported in U/mL
Agarose Gel Diffusion Method
In this simplified variant, EA cells are incorporated into an agarose layer and serum is placed in punched wells. Radial zones of hemolysis develop during incubation, and the zone diameter is compared against a standard curve of pooled reference serum. The method is semi-quantitative but more robust to pipoding variation and is suited to screening applications.
Alternative Platform Methods
- ELISA-based pathway-specific assays using microplates coated with immune complexes and detection of the terminal C5b-9 neoepitope
- Automated liposome-based assays in which complement-mediated liposome lysis releases a measurable marker, adapted to clinical chemistry analyzers
- Immunoturbidimetric or nephelometric quantification of individual C3 and C4 proteins for component-level assessment
Quality Control and Standardization
Reliable reports depend on calibrated spectrophotometers, freshly prepared or validated EA cell suspensions, reference sera traceable to WHO International Standard preparations where available, and documented low and high control performance within laboratory-defined limits. Replicate precision, typically expressed as the coefficient of variation, should meet the laboratory's acceptance criteria before patient results are released.
Report Interpretation and Result Analysis
Reference Values
Typical adult serum CH50 values fall within an approximate range of 50 to 100 U/mL, although the exact interval is method-dependent and each laboratory must establish and publish its own reference range. Results must always be interpreted against the interval printed on the specific report.
Decreased CH50 Results
- Hereditary deficiency of a classical pathway component, suggested by activity near zero with otherwise unexplained findings
- Complement consumption in immune complex diseases, including systemic lupus erythematosus, cryoglobulinemia, and post-infectious glomerulonephritis
- Infectious activation, as in subacute bacterial endocarditis and sepsis
- Reduced hepatic synthesis in advanced liver disease or severe malnutrition
- Pre-analytical degradation from delayed processing, warm storage, or repeated freeze-thaw cycles, which is the most common cause of spurious low results
Increased CH50 Results
Elevated activity is frequently observed as part of the acute-phase response, during pregnancy, after trauma or surgery, in inflammatory conditions, and in some malignancies. Elevated results carry limited specific diagnostic weight but confirm intact classical pathway function.
Critical Result Flags
Absent or near-absent CH50 in a properly handled specimen warrants urgent communication and reflex testing, as it strongly suggests hereditary complement deficiency, which carries significant clinical implications for infection susceptibility and autoimmune risk.
Applications
CH50 testing and its related hemolytic assays serve diverse clinical and industrial purposes:
- Evaluation of patients with recurrent pyogenic infections or suspected immunodeficiency
- Diagnosis and disease activity monitoring in systemic lupus erythematosus and other immune complex disorders, where falling CH50 parallels disease flares
- Workup of hereditary angioedema in conjunction with C4 and C1 inhibitor testing
- Transplantation and infusion-related reaction investigations
- Pharmaceutical development, including complement-dependent cytotoxicity assessment of therapeutic antibodies
- Research on complement-targeted therapeutics and immune pathway characterization
Related Hemolysis Testing for Medical Devices
Distinct from serum complement testing, direct hemolysis rate evaluation of medical device materials and biomaterials is performed according to ISO 10993-4 (identical in principle to GB/T 16886.4) and ASTM F756. In these biocompatibility protocols, materials are extracted or placed in direct contact with human or rabbit blood, and the released hemoglobin is quantified. A hemolysis rate below 5% is conventionally accepted as non-hemolytic. Accredited third-party laboratories routinely conduct this testing to support regulatory submissions for blood-contacting devices, and understanding the distinction between material-induced hemolysis testing and CH50 complement assays is important when commissioning test reports.
FAQ
Why is the 50% endpoint used instead of 100% hemolysis?
The sigmoidal dose-response curve of complement-mediated lysis is steepest at the 50% point, so this endpoint offers the greatest analytical sensitivity. Near 0% and 100% lysis, even large changes in complement concentration produce minimal measurable differences.
What does a low CH50 result mean?
A low result indicates reduced classical pathway function, caused either by consumption during immune complex disease or infection, reduced synthesis in liver disease, hereditary component deficiency, or specimen handling artifacts. Correlation with C3, C4, and AH50 results helps distinguish among these causes.
Can a hemolyzed sample be tested?
No. Pre-existing hemolysis releases hemoglobin into the serum, which is indistinguishable from assay-generated hemolysis by spectrophotometry and invalidates the measurement. Such specimens must be recollected.
How should samples be stored and shipped?
Serum should be separated promptly, kept at 2-8 degrees Celsius if tested within 24 hours, or frozen at -70 degrees Celsius for longer storage. Shipping must maintain the cold chain, and freeze-thaw cycles must be strictly minimized.
What is the difference between CH50 and C3 or C4 measurements?
CH50 is a functional assay requiring every classical component to be present and active, whereas C3 and C4 are quantitative protein concentration measurements. A single deficient component can abolish CH50 while individual protein levels appear normal.
How are results from different methods compared?
Because reference intervals and units vary among tube dilution, gel diffusion, ELISA, and automated platforms, results should only be compared against the reference range of the method that generated them. Serial monitoring should consistently use the same laboratory and method.
